Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

336
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
336
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

215
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
215
Parametric Survival Analysis: Weibull and Exponential Methods01:14

Parametric Survival Analysis: Weibull and Exponential Methods

694
Parametric survival analysis models survival data by assuming a specific probability distribution for the time until an event occurs. The Weibull and exponential distributions are two of the most commonly used methods in this context, due to their versatility and relatively straightforward application.
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...
694
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

298
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
298
Survival Tree01:19

Survival Tree

178
Survival trees are a non-parametric method used in survival analysis to model the relationship between a set of covariates and the time until an event of interest occurs, often referred to as the "time-to-event" or "survival time." This method is particularly useful when dealing with censored data, where the event has not occurred for some individuals by the end of the study period, or when the exact time of the event is unknown.
 Building a Survival Tree
Constructing a...
178
The Mantel-Cox Log-Rank Test01:19

The Mantel-Cox Log-Rank Test

630
The Mantel-Cox log-rank test is a widely used statistical method for comparing the survival distributions of two groups. It tests whether a statistically significant difference exists in survival times between the groups without assuming a specific distribution for the survival data, making it a non-parametric test. This flexibility makes the log-rank test particularly valuable in medical research and other fields where the timing of an event, such as death or disease recurrence, is of...
630

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Minimum distance estimation of mean and standard deviation from reported quantiles.

Research synthesis methods·2026
Same author

Rising burden of atrial fibrillation relative to other major cardiovascular diseases: nationwide trends over 2000-2022 and projections to 2040.

European journal of preventive cardiology·2026
Same author

Age- and Sex-Adjusted Myocardial Flow Reserve Percentiles for Personalized Cardiovascular Risk Assessment.

medRxiv : the preprint server for health sciences·2026
Same author

Enhancing Representation and Reporting of Body Mass Index in Cancer Randomized Clinical Trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Meta-analytic evaluation of surrogate endpoints at multiple time points in randomized controlled trials with time-to-event endpoints.

Clinical trials (London, England)·2025
Same author

Smartphone App-Based Survey Deployment Patterns and Longitudinal Response Rate: Randomized Controlled Trial.

Journal of medical Internet research·2025

Related Experiment Video

Updated: Oct 10, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.4K

Bayesian multivariate network meta-analysis model for the difference in restricted mean survival times.

Xiaoyu Tang1, Ludovic Trinquart1,2,3

  • 1Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA.

Statistics in Medicine
|December 9, 2021
PubMed
Summary

This study introduces a new network meta-analysis (NMA) model for survival data. The novel multiple-time-point model improves precision and detects benefits earlier than traditional methods.

Keywords:
clinical trials as topicnetwork meta-analysisnon-small cell lung cancerrestricted mean survival timesurvival analysis

More Related Videos

Measurement of Survival Time in Brachionus Rotifers: Synchronization of Maternal Conditions
05:18

Measurement of Survival Time in Brachionus Rotifers: Synchronization of Maternal Conditions

Published on: July 22, 2016

8.5K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.2K

Related Experiment Videos

Last Updated: Oct 10, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.4K
Measurement of Survival Time in Brachionus Rotifers: Synchronization of Maternal Conditions
05:18

Measurement of Survival Time in Brachionus Rotifers: Synchronization of Maternal Conditions

Published on: July 22, 2016

8.5K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.2K

Area of Science:

  • Biostatistics
  • Clinical Epidemiology
  • Medical Data Analysis

Background:

  • Network meta-analysis (NMA) is crucial for comparing multiple treatments.
  • Conventional NMA for time-to-event data often uses hazard ratios and ignores varying follow-up times.
  • This limitation impacts clinical decision-making for indications like lung cancer.

Purpose of the Study:

  • To develop a novel multivariate NMA model for restricted mean survival time (RMST) differences.
  • To synthesize evidence from multiple time points simultaneously, accounting for within-study and between-study correlations.
  • To improve the precision and interpretability of treatment effect comparisons in NMA.

Main Methods:

  • Developed a multivariate NMA model for RMST differences across multiple time points.
  • Proposed an estimator for within-study covariance, assuming it known for model estimation.
  • Employed a Bayesian framework for model estimation.
  • Utilized a simulation study to evaluate model performance.

Main Results:

  • The multiple-time-point model demonstrated lower mean squared error compared to single-time-point models across all time points.
  • Performance gains were particularly notable when evidence availability decreased.
  • Application to second-line non-small-cell lung cancer treatments showed increased precision and earlier detection of benefits.

Conclusions:

  • The proposed multiple-time-point NMA model offers a more precise and informative approach for analyzing time-to-event data.
  • This method enhances clinical decision-making by providing clinically interpretable measures and detecting treatment benefits earlier.
  • The model effectively synthesizes evidence across multiple time points, overcoming limitations of conventional NMA.